PLRZ
Polyrizon Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$10.99
−0.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.01
From 52W high−35.99%
Volume31962.00
Market cap$26.40M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$11.01
From 52W high
−35.99%
Volume
31962.00
Market cap
$26.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
P/E (TTM)
—
RSI (14)
41.7
MomentumView details →
1D Return
−0.36%
YTD Return
+21.81%
SummaryUpdated Dec 1, 2025
Polyrizon Ltd. (NASDAQ:PLRZ) is an Israeli biotechnology company founded in 2005 and headquartered in Ra'anana, Israel. The company went public on October 29, 2024, making it one of the newest entrants to the public markets in the biotech sector. Polyrizon specializes in developing innovative medical device hydrogels delivered through nasal spray formulations designed to create protective barriers against viruses and allergens. As a pre-revenue biotech company, Polyrizon is currently in the development phase of its product pipeline, focusing on respiratory protection and allergy management solutions.
Similar companies
Latest newsMore news →
Polyrizon Ltd. entered into definitive agreements with a single institutional investor for a registered direct offering of ordinary shares and pre-funded warrants, plus a concurrent private placement of pre-funded and investor warrants, expecting aggregate gross proceeds of approximately $4.0 million.17d agoPolyrizon completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study and is advancing toward enrollment of 120 patients.31d ago